Iza-Bren Beats Chemo in Second-Line Esophageal Cancer

by | Jun 3, 2026 | Health

Spread the love
In a phase 3 trial, izalontamab brengitecan shows superiority to chemotherapy in previously treated esophageal squamous cell carcinoma, but questions remain about generalizability outside China.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments